ArticleCureus2026
Associations Between Depression and Gastrointestinal Disorders in a Large Real-World Cohort.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) commonly coexist with depression; however, large-scale data on this relationship remain limited. We conducted a retrospective cohort study utilizing the TriNetX database to evaluate direction-specific associations between gastrointestinal (GI) disorders and depression. Methodology Adults aged 18-65 years with new diagnoses of IBS, IBD, and depression were included. Cohorts were matched to controls without the index condition, and the one-year incidence of new-onset depression after IBS or IBD and new-onset IBS or IBD after depression was assessed. We also examined the one-year depression risk among IBD patients treated with sulfasalazine compared with those treated with no sulfasalazine and mesalamine. Results Within one year, 6.2% of IBS patients developed depression versus 3.1% of controls (absolute risk difference = 3.1 percentage points; risk ratio (RR) = 2.00, 95% confidence interval (CI) = 1.97-2.03), and 3.9% of IBD patients developed depression versus 2.8% of controls (absolute risk difference = 1.1 percentage points; RR = 1.38, 95% CI = 1.35-1.41). In patients with depression, 0.83% developed IBS versus 0.37% of controls (absolute risk difference = 0.46 percentage points; RR = 2.25, 95% CI = 2.21-2.28), and 0.24% developed IBD versus 0.16% of controls (absolute risk difference = 0.08 percentage points; RR = 1.47, 95% CI = 1.44-1.51). In IBD patients, sulfasalazine use was associated with a higher incidence of depression compared with no sulfasalazine (12.9% vs. 3.1%; RR = 4.14, 95% CI = 3.53-4.85) and mesalamine (12.8% vs. 10.6%; RR = 1.21, 95% CI = 1.09-1.34). Conclusions In this large retrospective cohort study, GI disorders and depression were associated with increased risk of subsequent diagnoses in separate temporal analyses. These findings support existing literature and highlight the need for further research to clarify these mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.